These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 17054361)

  • 1. Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis.
    Ang WH; Daldini E; Scolaro C; Scopelliti R; Juillerat-Jeannerat L; Dyson PJ
    Inorg Chem; 2006 Oct; 45(22):9006-13. PubMed ID: 17054361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes.
    Scolaro C; Bergamo A; Brescacin L; Delfino R; Cocchietto M; Laurenczy G; Geldbach TJ; Sava G; Dyson PJ
    J Med Chem; 2005 Jun; 48(12):4161-71. PubMed ID: 15943488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.
    Peacock AF; Habtemariam A; Fernández R; Walland V; Fabbiani FP; Parsons S; Aird RE; Jodrell DI; Sadler PJ
    J Am Chem Soc; 2006 Feb; 128(5):1739-48. PubMed ID: 16448150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tuning the hydrolytic aqueous chemistry of osmium arene complexes with N,O-chelating ligands to achieve cancer cell cytotoxicity.
    Peacock AF; Parsons S; Sadler PJ
    J Am Chem Soc; 2007 Mar; 129(11):3348-57. PubMed ID: 17319668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, characterization, and in vitro evaluation of novel ruthenium(II) eta6-arene imidazole complexes.
    Vock CA; Scolaro C; Phillips AD; Scopelliti R; Sava G; Dyson PJ
    J Med Chem; 2006 Sep; 49(18):5552-61. PubMed ID: 16942028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Organometallic chemistry, biology and medicine: ruthenium arene anticancer complexes.
    Yan YK; Melchart M; Habtemariam A; Sadler PJ
    Chem Commun (Camb); 2005 Oct; (38):4764-76. PubMed ID: 16193110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel ruthenium(II) arene based intercalator with potent anticancer activity.
    Ruiz J; Vicente C; de Haro C; Bautista D
    Dalton Trans; 2009 Jul; (26):5071-3. PubMed ID: 19562164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands.
    Habtemariam A; Melchart M; Fernandez R; Parsons S; Oswald ID; Parkin A; Fabbiani FP; Davidson JE; Dawson A; Aird RE; Jodrell DI; Sadler PJ
    J Med Chem; 2006 Nov; 49(23):6858-68. PubMed ID: 17154516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA interactions of monofunctional organometallic ruthenium(II) antitumor complexes in cell-free media.
    Novakova O; Chen H; Vrana O; Rodger A; Sadler PJ; Brabec V
    Biochemistry; 2003 Oct; 42(39):11544-54. PubMed ID: 14516206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arene ruthenium complexes as anticancer agents.
    Süss-Fink G
    Dalton Trans; 2010 Feb; 39(7):1673-88. PubMed ID: 20449402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ruthenium(II) arene PTA (RAPTA) complexes: impact of enantiomerically pure chiral ligands.
    Kilpin KJ; Cammack SM; Clavel CM; Dyson PJ
    Dalton Trans; 2013 Feb; 42(6):2008-14. PubMed ID: 23187957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenylazo-pyridine and phenylazo-pyrazole chlorido ruthenium(II) arene complexes: arene loss, aquation, and cancer cell cytotoxicity.
    Dougan SJ; Melchart M; Habtemariam A; Parsons S; Sadler PJ
    Inorg Chem; 2006 Dec; 45(26):10882-94. PubMed ID: 17173447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of ruthenium antitumor drugs that overcome multidrug resistance mechanisms.
    Vock CA; Ang WH; Scolaro C; Phillips AD; Lagopoulos L; Juillerat-Jeanneret L; Sava G; Scopelliti R; Dyson PJ
    J Med Chem; 2007 May; 50(9):2166-75. PubMed ID: 17419606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arene control over thiolate to sulfinate oxidation in albumin by organometallic ruthenium anticancer complexes.
    Hu W; Luo Q; Ma X; Wu K; Liu J; Chen Y; Xiong S; Wang J; Sadler PJ; Wang F
    Chemistry; 2009 Jul; 15(27):6586-94. PubMed ID: 19533706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chloro half-sandwich osmium(II) complexes: influence of chelated N,N-ligands on hydrolysis, guanine binding, and cytotoxicity.
    Peacock AF; Habtemariam A; Moggach SA; Prescimone A; Parsons S; Sadler PJ
    Inorg Chem; 2007 May; 46(10):4049-59. PubMed ID: 17441712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular delivery of pyrenyl-arene ruthenium complexes by a water-soluble arene ruthenium metalla-cage.
    Furrer MA; Schmitt F; Wiederkehr M; Juillerat-Jeanneret L; Therrien B
    Dalton Trans; 2012 Jun; 41(24):7201-11. PubMed ID: 22506276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From hydrolytically labile to hydrolytically stable Ru(II)-arene anticancer complexes with carbohydrate-derived co-ligands.
    Hanif M; Meier SM; Kandioller W; Bytzek A; Hejl M; Hartinger CG; Nazarov AA; Arion VB; Jakupec MA; Dyson PJ; Keppler BK
    J Inorg Biochem; 2011 Feb; 105(2):224-31. PubMed ID: 21194622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Am(m)ines make the difference: organoruthenium am(m)ine complexes and their chemistry in anticancer drug development.
    Babak MV; Meier SM; Legin AA; Adib Razavi MS; Roller A; Jakupec MA; Keppler BK; Hartinger CG
    Chemistry; 2013 Mar; 19(13):4308-18. PubMed ID: 23341078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maltol-derived ruthenium-cymene complexes with tumor inhibiting properties: the impact of ligand-metal bond stability on anticancer activity in vitro.
    Kandioller W; Hartinger CG; Nazarov AA; Bartel C; Skocic M; Jakupec MA; Arion VB; Keppler BK
    Chemistry; 2009 Nov; 15(45):12283-91. PubMed ID: 19821465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Half-sandwich Ru II[9]aneS3 complexes structurally similar to antitumor-active organometallic piano-stool compounds: preparation, structural characterization and in vitro cytotoxic activity.
    Bratsos I; Jedner S; Bergamo A; Sava G; Gianferrara T; Zangrando E; Alessio E
    J Inorg Biochem; 2008; 102(5-6):1120-33. PubMed ID: 18279961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.